Halozyme Therapeutics sinks after confirming $2B Evotec buyout offer
Halozyme Therapeutics (NASDAQ:HALO) fell 14% after confirming on Thursday that it made an €11 per share bid for Evotec .
Zacks.com on MSN17h
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...
Hosted on MSN21h
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid
Halozyme Therapeutics (NASDAQ:HALO) announced on Thursday its plans to acquire German drug developer Evotec SE ADR ...
GameRant on MSN17h
What to Expect From Call of Duty: Black Ops 6's Rumored Halo Crossover
A lot of rumors are starting to surface surrounding the first major crossovers for Call of Duty: Black Ops 6, such as a ...